Overview of Economic Analysis of Le Chevalier Vinorelbine Study

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 4, 1998, Pages 14-16

  Hillner, Bruce E ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH ECONOMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; VINBLASTINE;

EID: 0031971044     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Eisenberg JM: Clinical economics. A guide to the economic analysis of clinical practices. JAMA 262:2879-2886, 1989.
2. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993.
3. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small-cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993.
4. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16,1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
5. Smith TJ, Hillner BE, Neighbors DM, et al Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 13:2166-2173, 1995.
6. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients J Clin Oncol 12.360-367, 1994.